KSPHF.US Kissei Pharmaceutical Co. Ltd

Healthcare Pharmaceuticals USA Stocks
24.50 USD
Close of Nov 15, 2026
23.16 29.44
Market cap
USD 1.02B
P/E
14.4x
P/B
0.72x
ROE
4.5%
Dividend yield
3.32%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.

Is KSPHF.US undervalued?

Graham number
Price24.50
Graham value36.18
Discount32.3%

KSPHF.US trades 32.3% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Kissei Pharmaceutical Co. Ltd fundamental analysis

No fundamental analysis for Kissei Pharmaceutical Co. Ltd yet.

Kissei Pharmaceutical Co. Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Kissei Pharmaceutical Co. Ltd

Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan and internationally. It offers Calogra tablets, for the treatment of ulcerative colitis; Tabneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Corsuba Intravenous Dialysis Syringe for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Da…

Full company profile